Is a complete ZBIO research report available?

No complete published report is available for Zenas BioPharma, Inc. (ZBIO) on this page. Market-directory data, when present, is not a substitute for a reviewed stock analysis.

Zenas BioPharma, Inc. (ZBIO)

NASDAQ: ZBIO · USD

$31.1

-1.20 (-3.7%)· Recorded snapshot

Coverage state: Market snapshot only — no published research

Market snapshot recorded 2026-07-30 02:00 UTC. No published research is attached to this ticker. Prices and fundamentals on this server-rendered page are dated snapshots, not a real-time trading feed.

On-demand research

Generate the first ZBIO analysis

Start the full research workflow when this ticker is ready in our data system.

Market cap	2B
Net income (ttm)	-425.2M
EPS (ttm)	-$8.82
Shares out	63.1M
Volume	625,580
Price target	$43.5	+39.9%

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Net income (ttm): -425.2M
EPS (ttm): -$8.82
Market cap: 2B

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
ALNY	Alnylam Pharmaceuticals, Inc.	38.3B	72.6x	8.9x	78.4%	+49.7%	-11.8%	Strong Buy
ARGX	argenx SE	55.2B	32.2x	10.4x	50.6%	+58.8%	+48.3%	Strong Buy
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Hold

All ZBIO indicators

Market & fundamental data

Available fields

178

Groups with data

Currency

USD

Showing 178 of 178 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0001953926
Company name	Zenas BioPharma, Inc.
Country	United States
Country code	US
Cusip	98937L105
Employees	167
Employees Change	37%
Employees Change Percent	28.46
Enterprise value	$1.5B
Exchange	NASDAQ
Financial currency	USD
First seen	2026-05-09
Industry	Biotechnology
IPO Date	2024-09-13
Isin	US98937L1052
Last refreshed	2026-07-30
Market cap	$2B
Market cap category	Mid-Cap
Price	$31.09
Price currency	USD
Sector	Healthcare
Sector PE	45.6
Sector PE Fwd	24.3
Sic	2834
Symbol	ZBIO
Website	https://zenasbio.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-21.66%
EV Sales Forward	41.71x
FCF yield	-10.72%
P/B ratio	5.78x
PS Forward	54.13x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Gross Profit	$-193.6M
Net Income	$-425.2M
Net Income Growth Years	0%
Profit Per Employee	$-2.5M
ROA	-29.06
ROCE	-61.63
ROE	-137.1
ROIC	-35.38

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr1y	89.08%
EPS Growth Years	2
Revenue Growth	100x
Revenue Growth Years	1x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Assets	$747.7M
Cash	$717.2M
Current Assets	$730.2M
Current Liabilities	$61.2M
Debt	$266.8M
Debt Equity	$0.79
Equity	$335.8M
Interest Coverage	-30.31
Liabilities	$411.9M
Long Term Assets	$17.5M
Long Term Liabilities	$350.7M
Net Cash	$450.4M
Net Cash By Market Cap	$22.95
Net Cash Growth	44.74%
Net Debt Equity	$-1.34
Tangible Book Value	$335.8M
Tangible Book Value Per Share	$5.38

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	11.94
Net Working Capital	$-47.2M
Quick ratio	11.74
Working Capital	$669M

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-107.16%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
1Y total return	89%
200-day SMA	25.68
50-day SMA	23.58
50-day SMA vs 200-day SMA	50under200
All Time High	44.6
All Time High Change	-30.29%
All Time High Date	2025-12-24
All Time Low	5.83
All Time Low Change	433.28%
All Time Low Date	2025-01-28
ATR	1.91
Beta1y	-0.26
Beta2y	0.43
Ch YTD	-14.38
High	32.43
High52	44.6
High52 Date	2025-12-24
High52ch	-30.29%
Low	30.25
Low52	13.5
Low52 Date	2026-01-05
Low52ch	130.3%
Ma50ch	31.88%
Price vs 200-day SMA	21.06%
RSI	61.12
RSI Monthly	60.24
RSI Weekly	63.03
Sharpe ratio	1.15x
Sortino ratio	1.7
Total Return	-107.16%
Tr YTD	-14.38
Tr1m	20.18%
Tr1w	-1.27%
Tr3m	72.63%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	8
Analyst Count Top	5
Analyst Price Target Top	$48
Analyst Ratings	Strong Buy
Analyst Ratings Top	Strong Buy
Earnings EPS Estimate	$-0.78
Earnings Revenue Estimate	27,000,000x
Operating Income	$-251.4M
Price target	$43.5
Price Target Change	$39.92
Price Target Change Top	$54.39

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	41,062,189%
Float Percent	65.04%
Net Borrowing	267,500,000
Shares Insiders	1.57%
Shares Institutions	74.55%
Shares Out	63,133,377
Shares Qo Q	4.95%
Shares Yo Y	107.16%
Short Float	29.64%
Short Ratio	11.05
Short Shares	19.28

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$-240.6M
Adjusted OCF	-240,634,000
Average Volume	935,721.65x
Bv Per Share	5.38
CAPEX	$-2,000
Ch1m	20.18
Ch1w	-1.27
Ch1y	89
Ch3m	72.63
Ch6m	44.81
Change	-3.72%
Change From Open	-4.13
Close	32.29
Days Gap	0.43
Depreciation Amortization	39,000
Dollar Volume	19,449,282.2
Earnings Date	2026-08-13
Earnings Time	bmo
EBIT	$-423.1M
EBITDA	$-423M
EPS	$-8.82
F Score	2
FCF	$-210.5M
FCF EV Yield	-13.92x
FCF Per Share	$-3.33
Financing CF	648,660,000
Fiscal Year End	December
Founded	2,019
Income Tax	$126,000
Investing CF	-134,001,000
Ipr	82.88
Iprfo	69.43
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-05-13
Last Report Date	2026-03-31
Last Split Type	Never
Last10k Filing Date	2026-03-16
Ma150	23.18
Ma150ch	34.14%
Ma20	29.61
Ma20ch	4.99%
Net CF	303,670,000
Next Earnings Date	2026-08-11
Open	32.43
Optionable	Yes
Position In Range	38.53
Ppne	1,118,000
Price Date	2026-07-29
Ptbv Ratio	5.84
Relative Volume	0.67x
Share Based Comp	30,156,000
Tr6m	44.81%
Us State	Massachusetts
Volume	625,580
Z Score	-0.15

Zenas BioPharma, Inc. (ZBIO)

Coverage state: Market snapshot only — no published research

Generate the first ZBIO analysis

Price

Financial snapshot

Fair-value bridge

Analyst consensus

Latest news · ZBIO

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All ZBIO indicators

Profile and market data

Valuation

Profitability

Growth

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Analyst estimates

Ownership and float

Other indicators

Deeper analysis on ZBIO

Frequently asked questions